Filing Flows › Janux Therapeutics (JANX) › Q2 2026
Janux Therapeutics (JANX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Janux Therapeutics (JANX) reported revenue of $10.3M for the second quarter 2026 (Q2 2026) and +175% from the quarter before. Operating margin was -308.7%, net loss $22.0M (214.0% of revenue).
Janux Therapeutics, Q2 2026: revenue $10.3M, operating margin -308.7%, net loss $22.0M, operating cash flow $12.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.3M | +175% | — |
| Operating profit | −$31.7M | — | — |
| Net earnings | −$22.0M | — | — |
| Operating cash flow | $12.5M | — | — |
| Free cash flow | $12.3M | — | — |
What changed
Revenue was $10.3M in Q2 2026, up 175% from the previous quarter.
Operating costs exceeded revenue by $31.7M, an operating margin of -308.7%. The quarter ended with a net loss of $22.0M, narrower than the previous quarter's $24.4M loss. Non-operating items added $9.7M, -44% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $12.5M. Non-cash charges added back $463K of depreciation and $9.1M of share-based compensation. Working capital and other items added $24.9M. Capital expenditures of $202K left free cash flow of $12.3M.
Questions
What was Janux Therapeutics' revenue in the second quarter 2026?
Janux Therapeutics (JANX) reported revenue of $10.3M for the second quarter 2026 (Q2 2026) and +175% from the quarter before.
Was Janux Therapeutics profitable in the second quarter 2026?
Operating loss was $31.7M (-308.7% of revenue) and net loss $22.0M.
Source: Janux Therapeutics 10-Q on SEC EDGAR.